Floatz logo

mt027 car-t cells

Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

T-MAXIMUM Pharmaceutical IncCell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
National Cancer Institute (NCI)
Phase 2B
Eflornithine
Mayo Clinic
Phase 1/2CCC
ADVICOR COMPONENT NIACIN
AHS Cancer Control Alberta
Phase 1/2CC
LMP744
National Institute of Neurological Disorders and Stroke (NINDS)
Phase 1/2CC
Debio 0123
Debiopharm International SA
Phase 1/2CC

Same molecule, other indications

mt027 car-t cells is also rated in:

primary peritoneal carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →